5-(4-amino-3-(2-aminopyrimidin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-N-hydroxypentanamide

ID: ALA4879240

PubChem CID: 164626077

Max Phase: Preclinical

Molecular Formula: C14H17N9O2

Molecular Weight: 343.35

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  Nc1ncc(-c2nn(CCCCC(=O)NO)c3ncnc(N)c23)cn1

Standard InChI:  InChI=1S/C14H17N9O2/c15-12-10-11(8-5-17-14(16)18-6-8)21-23(13(10)20-7-19-12)4-2-1-3-9(24)22-25/h5-7,25H,1-4H2,(H,22,24)(H2,15,19,20)(H2,16,17,18)

Standard InChI Key:  FWQRRUGYGADOJJ-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 25 27  0  0  0  0  0  0  0  0999 V2000
   16.4827   -5.0476    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.4816   -5.8671    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   17.1896   -6.2761    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.1878   -4.6387    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   17.8965   -5.0440    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.9013   -5.8626    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.6813   -6.1110    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.1587   -5.4459    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.6735   -4.7865    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   17.1907   -7.0933    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.9215   -4.0078    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.7198   -3.8333    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.9678   -3.0546    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.7661   -2.8800    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.0141   -2.1013    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.8124   -1.9267    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   20.4637   -1.4973    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   22.0604   -1.1481    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   18.9370   -6.8822    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.3920   -7.4926    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.6485   -8.2677    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   19.7343   -7.0454    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.9937   -7.8182    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   19.4524   -8.4329    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.7118   -9.2078    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  6  2  0
  5  4  2  0
  4  1  1  0
  5  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9  5  1  0
  3 10  1  0
  9 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
 15 17  2  0
 16 18  1  0
 19 20  2  0
 20 21  1  0
 21 24  2  0
 23 22  2  0
 22 19  1  0
  7 19  1  0
 23 24  1  0
 24 25  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4879240

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 343.35

Molecular Weight (Monoisotopic): 343.1505

AlogP: 0.12

#Rotatable Bonds: 6

Polar Surface Area: 170.75

Molecular Species: NEUTRAL

HBA: 10

HBD: 4

#RO5 Violations: ┄

HBA (Lipinski): 11

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 8.91

CX Basic pKa: 3.95

CX LogP: -0.77

CX LogD: -0.79

Aromatic Rings: 3

Heavy Atoms: 25

QED Weighted: 0.28

Np Likeness Score: -0.90

References

1. Zhang M, Wei W, Peng C, Ma X, He X, Zhang H, Zhou M..  (2021)  Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy.,  49  [PMID:34314844] [10.1016/j.bmcl.2021.128286]

Source

Source(1):

• Scientific Literature